Isatin come on the stage of CDK4/6 inhibitor

  • Radiktya Surya Pradana Department of Pharmacy, Faculty of Health Sciences, Universitas Jenderal Soedirman, Purwokerto 53123, Indonesia
  • Muhammad Salman Fareza Department of Pharmacy, Faculty of Health Sciences, Universitas Jenderal Soedirman, Purwokerto 53123, Indonesia https://orcid.org/0000-0003-2414-1249
Keywords: CDK4/6 inhibitor, cancer, metastasis, breast cancer

Abstract

Cyclin-dependent kinase (CDK) 4/6 inhibitors have significantly improved the prognosis for patients with hormone receptor-positive (HR+) and human epidermal growth factor receptor 2-negative (HER2-) breast cancer, including those with metastatic or advanced breast cancer (mBC/ABC). Recent research has focused on developing CDK4/6 inhibitors with diverse structural frameworks, including isatin-based compounds. Isatin and its derivatives have shown promise in inhibiting CDK4/6, with potential efficacy against breast cancer cell lines. Studies have also indicated that isatinyl-2-aminobenzoylhydrazone (ISABH) complexes, particularly those with transition metals like nickel (Ni-ISABH), exhibit strong binding affinities to CDK6 and fulfill key pharmacokinetic criteria.

References

Pandey, K., An, H.-J., Kim, S.K., Lee, S.A., Kim, S., Lim, S.M., Kim, G.M., Sohn, J. and Moon, Y.W. 2019. Molecular mechanisms of resistance to CDK4/6 inhibitors in breast cancer: A review. International Journal of Cancer.2019;145(5):1179-1188. https://doi.org/10.1002/ijc.32020

Jhaveri, K., Burris Rd, H.A., Yap, T.A., Hamilton, E., Rugo, H.S., Goldman, J.W., Dann, S., Liu, F., Wong, G.Y., Krupka, H. and Shapiro, G.I. The evolution of cyclin dependent kinase inhibitors in the treatment of cancer. Expert Review of Anticancer Therapy.2021.https://doi.org/10.1080/14737140.2021.1944109

Yousuf, M., Khan, P., Shamsi, A., Shahbaaz, M., Hasan, G.M., Haque, Q.M.R., Christoffels, A., Islam, A. and Hassan, M.I. 2020. Inhibiting CDK6 activity by quercetin is an attractive strategy for cancer therapy. ACS omega.2020;5(42): 27480-27491. https://doi.org/10.1021/acsomega.0c03975

Nusantoro, YR. and Fadlan, A. In silico studies of isatinyl-2-aminobenzoylhydrazone transition metal complexes against cyclin-dependent kinase 6 (CDK6). Pharmacy Reports, 2021;1(1):4. https://doi.org/10.51511/pr.4

Published
2022-12-31
How to Cite
Pradana, R. S., & Fareza, M. S. (2022). Isatin come on the stage of CDK4/6 inhibitor. Pharmacy Reports, 2(2), 12. https://doi.org/10.51511/pr.12
Section
Perspectives